LV10923B - Derivates of penciclovir for the treatment of hepatitis- b infections - Google Patents

Derivates of penciclovir for the treatment of hepatitis- b infections Download PDF

Info

Publication number: LV10923B
Authority: LV; Latvia
Prior art keywords: compound; formula; use according; hepatitis; treatment
Prior art date: 1989-03-03

Application number

LVP-95-253A

Other languages

English (en)

Latvian (lv)

Other versions

LV10923A (lv

Inventor

Malcolm Richard Boyd

David Sutton

Original Assignee

Beecham Group Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-03-03

Filing date

1995-08-16

Publication date

1996-06-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10652653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV10923(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-08-16 Application filed by Beecham Group Plc filed Critical Beecham Group Plc

1995-12-20 Publication of LV10923A publication Critical patent/LV10923A/xx

1996-06-20 Publication of LV10923B publication Critical patent/LV10923B/en

Links

208000002672 hepatitis B Diseases 0.000 title claims abstract description 10
JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 title claims description 6
229960001179 penciclovir Drugs 0.000 title claims description 6
150000001875 compounds Chemical class 0.000 claims abstract description 41
150000003839 salts Chemical class 0.000 claims abstract description 13
125000002252 acyl group Chemical group 0.000 claims abstract description 9
229910019142 PO4 Inorganic materials 0.000 claims abstract description 6
239000010452 phosphate Substances 0.000 claims abstract description 6
-1 phosphate ester Chemical class 0.000 claims abstract description 6
239000003814 drug Substances 0.000 claims description 10
GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims description 6
229910052739 hydrogen Chemical group 0.000 claims description 6
239000001257 hydrogen Chemical group 0.000 claims description 6
229960004396 famciclovir Drugs 0.000 claims description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
238000007911 parenteral administration Methods 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 2
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
230000021736 acetylation Effects 0.000 claims 1
238000006640 acetylation reaction Methods 0.000 claims 1
239000002243 precursor Substances 0.000 claims 1
159000000000 sodium salts Chemical class 0.000 claims 1
229940002612 prodrug Drugs 0.000 abstract description 12
239000000651 prodrug Substances 0.000 abstract description 12
239000003981 vehicle Substances 0.000 description 6
230000000694 effects Effects 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 4
239000000203 mixture Substances 0.000 description 4
241000272517 Anseriformes Species 0.000 description 3
241000700721 Hepatitis B virus Species 0.000 description 3
125000003545 alkoxy group Chemical group 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
239000013011 aqueous formulation Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000000034 method Methods 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
NASFKTWZWDYFER-UHFFFAOYSA-N sodium;hydrate Chemical compound O.[Na] NASFKTWZWDYFER-UHFFFAOYSA-N 0.000 description 2
239000000725 suspension Substances 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000272525 Anas platyrhynchos Species 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
241000725618 Duck hepatitis B virus Species 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
241000700605 Viruses Species 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
238000004040 coloring Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
235000013312 flour Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
150000002431 hydrogen Chemical group 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000003305 oral gavage Methods 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
150000003014 phosphoric acid esters Chemical class 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
238000007789 sealing Methods 0.000 description 1
235000002639 sodium chloride Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LVP-95-253A 1989-03-03 1995-08-16 Derivates of penciclovir for the treatment of hepatitis- b infections LV10923B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB898904855A GB8904855D0 (en)	1989-03-03	1989-03-03	Pharmaceutical treatment

Publications (2)

Publication Number	Publication Date
LV10923A LV10923A (lv)	1995-12-20
LV10923B true LV10923B (en)	1996-06-20

Family

ID=10652653

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-95-253A LV10923B (en)	1989-03-03	1995-08-16	Derivates of penciclovir for the treatment of hepatitis- b infections

Country Status (18)

Country	Link
US (1)	US6136813A (de)
EP (1)	EP0388049B1 (de)
JP (1)	JP2513519B2 (de)
KR (1)	KR0143410B1 (de)
AT (1)	ATE122562T1 (de)
AU (1)	AU628137B2 (de)
CA (1)	CA2011238C (de)
CY (1)	CY1870A (de)
DE (1)	DE69019404T2 (de)
DK (1)	DK0388049T3 (de)
ES (1)	ES2072386T3 (de)
GB (1)	GB8904855D0 (de)
HK (1)	HK116795A (de)
HU (1)	HU205715B (de)
IE (1)	IE67125B1 (de)
IL (1)	IL93594A (de)
LV (1)	LV10923B (de)
ZA (1)	ZA901572B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9326177D0 (en) *	1993-12-22	1994-02-23	Smithkline Beecham Plc	Pharmaceuticals
US6124304A (en) *	1993-10-05	2000-09-26	Smithkline Beecham Plc	Penciclovir for the treatment of zoster associated pain
WO1995022330A1 (en) *	1994-02-17	1995-08-24	Commonwealth Scientific And Industrial Research Organisation	Antiviral agents
WO1996033720A1 (en) *	1995-04-24	1996-10-31	Smithkline Beecham Plc	Use of (r)-penciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases
WO1998023285A1 (en) *	1996-11-29	1998-06-04	Smithkline Beecham Plc	Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis b
US5939423A (en) *	1997-04-16	1999-08-17	Sciclone Pharmaceuticals, Inc.	Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir
AUPO912997A0 (en) *	1997-09-11	1997-10-02	Commonwealth Scientific And Industrial Research Organisation	Antiviral agents
US6288033B1 (en)	1998-09-25	2001-09-11	Sciclone Pharmaceuticals, Inc.	Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir
IL142910A0 (en) *	1998-11-02	2002-04-21	Triangle Pharmaceuticals Inc	Combination therapy to treat hepatitis b virus
AU2013257951A1 (en)	2012-05-11	2015-01-22	Akron Molecules Ag	Use of compounds for the treatment of pain

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4199574A (en) *	1974-09-02	1980-04-22	Burroughs Wellcome Co.	Methods and compositions for treating viral infections and guanine acyclic nucleosides
US4230708A (en) *	1977-10-20	1980-10-28	Stichting Rega V.Z.W.	Therapeutic application of (S) -or (RS)-9-(2, 3-dihydroxypropyl) adenine for use as antiviral agents
NL8202626A (nl) *	1982-06-29	1984-01-16	Stichting Rega V Z W	Derivaten van 9-(2-hydroxyethoxymethyl)guanine.
US4556659A (en) *	1982-08-09	1985-12-03	Syntex (U.S.A.) Inc.	Substituted 9-(1-0- or 3-0-monosubstituted or 1,3-Di-0-substituted propoxymethyl)-purines as antiviral agents
US4649140A (en) *	1982-10-14	1987-03-10	Burroughs Wellcome Co.	Purine derivatives
US5059604A (en) *	1982-10-14	1991-10-22	Burroughs Wellcome Co.	2-amino purine derivatives
EP0141927B1 (de) *	1983-08-18	1991-10-30	Beecham Group Plc	Antivirale Guanin-Derivate
IL73682A (en) *	1983-12-20	1991-08-16	Medivir Ab	Antiviral pharmaceutical compositions containing 9-hydroxy aliphatic derivatives of guanine,some new such derivatives and process for their preparation
EP0182024B1 (de) *	1984-09-20	1991-04-03	Beecham Group Plc	Purin-Derivate und ihre pharmazeutische Verwendung
SE8406538D0 (sv) *	1984-12-21	1984-12-21	Astra Laekemedel Ab	Novel derivatives of purine
EP0216459B1 (de) *	1985-07-27	1990-05-16	Beecham Group Plc	9-Substituierte Guaninmonohydrate
SE8602981D0 (sv) *	1986-07-04	1986-07-04	Astra Laekemedel Ab	Novel medicinal use
HU196038B (en) *	1987-08-07	1988-09-28	Mta Koezponti Kemiai Kutato In	Process for producing antiherpetic pharmaceutics for external use, containing 5-isopropyl-2'-beta-deoxy-uridine
SE8801729D0 (sv) *	1988-05-06	1988-05-06	Astra Ab	Purine derivatives for use in therapy
GB8823320D0 (en) *	1988-10-05	1988-11-09	Nycomed As	Chemical compounds

1989
- 1989-03-03 GB GB898904855A patent/GB8904855D0/en active Pending
1990
- 1990-03-01 EP EP90302186A patent/EP0388049B1/de not_active Expired - Lifetime
- 1990-03-01 DK DK90302186.3T patent/DK0388049T3/da active
- 1990-03-01 IE IE73390A patent/IE67125B1/en not_active IP Right Cessation
- 1990-03-01 ES ES90302186T patent/ES2072386T3/es not_active Expired - Lifetime
- 1990-03-01 HU HU901252A patent/HU205715B/hu unknown
- 1990-03-01 DE DE69019404T patent/DE69019404T2/de not_active Expired - Lifetime
- 1990-03-01 ZA ZA901572A patent/ZA901572B/xx unknown
- 1990-03-01 CA CA002011238A patent/CA2011238C/en not_active Expired - Lifetime
- 1990-03-01 AT AT90302186T patent/ATE122562T1/de not_active IP Right Cessation
- 1990-03-01 IL IL9359490A patent/IL93594A/en not_active IP Right Cessation
- 1990-03-01 AU AU50600/90A patent/AU628137B2/en not_active Expired
- 1990-03-02 JP JP2049722A patent/JP2513519B2/ja not_active Expired - Lifetime
- 1990-03-03 KR KR1019900002767A patent/KR0143410B1/ko not_active Expired - Fee Related
1994
- 1994-08-08 US US08/287,476 patent/US6136813A/en not_active Expired - Lifetime
1995
- 1995-07-13 HK HK116795A patent/HK116795A/en not_active IP Right Cessation
- 1995-08-16 LV LVP-95-253A patent/LV10923B/en unknown
1996
- 1996-04-05 CY CY187096A patent/CY1870A/xx unknown

Also Published As

Publication number	Publication date
IL93594A0 (en)	1990-12-23
ES2072386T3 (es)	1995-07-16
AU5060090A (en)	1990-11-01
IE67125B1 (en)	1996-03-06
IE900733L (en)	1990-09-03
ZA901572B (en)	1991-03-27
HK116795A (en)	1995-07-21
EP0388049A3 (de)	1991-11-06
EP0388049B1 (de)	1995-05-17
EP0388049A2 (de)	1990-09-19
KR900014385A (ko)	1990-10-23
JP2513519B2 (ja)	1996-07-03
HU205715B (en)	1992-06-29
HU901252D0 (en)	1990-05-28
CY1870A (en)	1996-04-05
LV10923A (lv)	1995-12-20
ATE122562T1 (de)	1995-06-15
US6136813A (en)	2000-10-24
DK0388049T3 (da)	1995-06-06
GB8904855D0 (en)	1989-04-12
JPH02275821A (ja)	1990-11-09
IL93594A (en)	1995-05-26
HUT53522A (en)	1990-11-28
DE69019404D1 (de)	1995-06-22
KR0143410B1 (ko)	1998-07-15
CA2011238C (en)	2000-03-28
AU628137B2 (en)	1992-09-10
DE69019404T2 (de)	1995-10-12
CA2011238A1 (en)	1990-09-03

Publication	Publication Date	Title
HU226778B1 (en)	2009-10-28	Injection and injection kit containing omeprazole and its analogs
EP0388049B1 (de)	1995-05-17	Derivate von Penciclovir zur Behandlung von Hepatitis-B-Infektionen
CA2086756C (en)	2003-04-08	Penciclovir and famciclovir and related guanine derivatives for the treatment of the hiv-1 infections
KR960014991B1 (ko)	1996-10-23	2',3'-디데옥시시티딘을 극히 저용량으로 함유하는 약제학적 조성물
US5840763A (en)	1998-11-24	Treatment of a latent infection of herpes viruses
JP2007297412A (ja)	2007-11-15	ヒト・ヘルペスウイルス−８の治療に対するペンシクロビルの使用
KR100341736B1 (ko)	2002-11-23	인간헤르페스바이러스7감염의치료및예방용2-아미노푸린유도체의용도
EP0728001B1 (de)	2001-12-19	Verwendung von 2-aminopurinderivaten zur behandlung und prophylaxe der menschlichen herpesvirus 6 infektionen
CN1084622C (zh)	2002-05-15	药物
JPH06227982A (ja)	1994-08-16	抗ウイルス剤
HK1004373B (en)	2004-08-13	Use of penciclovir for the treatment of human herpes-virus-8
HK1003259B (en)	2002-09-06	Use of aminopurine antiviral agents for the treatment and prophylaxis of latent herpesvirus infections
HK1012233B (en)	2002-10-04	Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 6 infections
MXPA97004336A (en)	1998-07-03	Use of antiviral agents for the treatment and prophylaxis of latent infections of herpesvi